Abstract:

Prevention strategies of post-endoscopic retrograde cholangiopancreatography pancreatitis      GUO Xue-gang, LUO Hui, ZHENG Liang. Endoscopy Center, Xijing Hospital of Digestive Diseases, the Fourth Military Medical University, Xi’an 710032, China
Corresponding author: GUO Xue-gang, E-mail：gxuegang@
fmmu.edu.cn
Abstract     Pancreatitis is the most common and serious complication of endoscopic retrograde cholangiopancreatography (ERCP). Rectal non-steroidal antiinflammatory drugs (NSAIDs) (indomethacin or diclofenac) and pancreatic stents are effective preventions of post-ERCP pancreatitis. Optimal ERCP perioperative management (preoperative risk evaluation, intraoperative risk management, postoperative active treatment) can reduce PEP risk effectively.

Key words: endoscopic retrograde cholangiopancreatography, pancreatitis, non-steroidal antiinflammatory drugs, stent

摘要：

胰腺炎是内镜逆行胰胆管造影（ERCP）术后最常见和最严重的并发症之一。目前，非甾体类抗炎药物（吲哚美辛栓或双氯芬栓）纳肛和预防性胰管支架植入是行之有效的ERCP术后胰腺炎（PEP）预防措施。优化ERCP围手术期管理(术前风险评估，术中风险控制，术后积极治疗)，可有效降低PEP风险。

关键词: 内镜逆行胰胆管造影, 胰腺炎, 非甾体抗炎药, 支架